46.81
0.65 (1.41%)
| Previous Close | 46.16 |
| Volume | 1,238,510 |
| Price / Sales | 13.14 |
| Price / Book | 23.92 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -2.55 |
| Total Debt/Equity (MRQ) | 20.22% |
| Current Ratio (MRQ) | 10.25 |
| Operating Cash Flow (TTM) | -229.84 M |
| Levered Free Cash Flow (TTM) | -134.32 M |
| Return on Assets (TTM) | -50.15% |
| Return on Equity (TTM) | -106.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Scholar Rock Holding Corporatio | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -2.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.35% |
| % Held by Institutions | 118.63% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HALLAL DAVID | - | 48.16 | -36,652 | -1,765,160 |
| WOODS KEITH | - | 48.61 | -48,034 | -2,334,933 |
| Aggregate Net Quantity | -84,686 | |||
| Aggregate Net Value ($) | -4,100,093 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 48.39 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WOODS KEITH | Officer | 24 Sep 2026 | Disposed (-) | 48,034 | 48.61 | 2,334,933 |
| HALLAL DAVID | Officer | 21 Sep 2026 | Disposed (-) | 36,652 | 48.16 | 1,765,160 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |